CureVac N.V [CVAC] vs Maze Therapeutics [MAZE] Detailed Stock Comparison

CureVac N.V.

NASDAQ
Loading...

Maze Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: CureVac N.V. wins in 12 metrics, Maze Therapeutics Inc. wins in 2 metrics, with 0 ties. CureVac N.V. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric CureVac N.V. Maze Therapeutics Inc. Better
P/E Ratio (TTM) 6.96 189.50 CureVac N.V.
Price-to-Book Ratio 0.83 3.68 CureVac N.V.
Debt-to-Equity Ratio 4.03 6.57 CureVac N.V.
PEG Ratio -0.35 -5.25 CureVac N.V.
EV/EBITDA 2.39 -7.11 CureVac N.V.
Profit Margin (TTM) 182.11% 0.00% CureVac N.V.
Operating Margin (TTM) 573.04% 0.00% CureVac N.V.
EBITDA Margin (TTM) 573.04% N/A N/A
Return on Equity 23.28% -47.52% CureVac N.V.
Return on Assets (TTM) 20.20% -28.01% CureVac N.V.
Free Cash Flow (TTM) $96.80M $-112.73M CureVac N.V.
1-Year Return 10.69% 164.34% Maze Therapeutics Inc.
Price-to-Sales Ratio (TTM) 14.83 N/A N/A
Enterprise Value $537.57M $998.67M Maze Therapeutics Inc.
EV/Revenue Ratio 6.53 N/A N/A
Gross Profit Margin (TTM) 99.31% N/A N/A
Revenue per Share (TTM) $0 N/A N/A
Earnings per Share (Diluted) $0.67 $-3.05 CureVac N.V.
Beta (Stock Volatility) 1.84 N/A N/A
Short % of Float 0.49% 9.32% CureVac N.V.

CureVac N.V. vs Maze Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

CVAC
MAZE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
CureVac N.V.0.00%4.02%-10.56%-13.86%-13.86%-0.21%
Maze Therapeutics Inc.2.35%-4.57%-7.69%-43.73%-40.08%-37.49%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
CureVac N.V.10.69%-54.49%-95.36%-91.66%-91.66%-91.66%
Maze Therapeutics Inc.164.34%65.89%65.89%65.89%65.89%65.89%

Performance & Financial Health Analysis: CureVac N.V. vs Maze Therapeutics Inc.

MetricCVACMAZE
Market Information
Market Cap i$1.05B$1.29B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,241,6611,174,955
90 Day Avg. Volume i1,688,6771,253,272
Last Close$4.66$24.86
52 Week Range$4.00 - $5.55$9.83 - $53.65
% from 52W High-16.04%-53.66%
All-Time High$151.80 (Dec 07, 2020)$53.65 (Mar 16, 2026)
% from All-Time High-96.93%-53.66%
Growth Metrics
Quarterly Revenue Growth-0.89%N/A
Quarterly Earnings Growth-0.19%N/A
Financial Health
Profit Margin (TTM) i1.82%0.00%
Operating Margin (TTM) i5.73%0.00%
Return on Equity (TTM) i0.23%-0.48%
Debt to Equity (MRQ) i4.036.57
Cash & Liquidity
Book Value per Share (MRQ)$5.63$7.20
Cash per Share (MRQ)$2.30$6.88
Operating Cash Flow (TTM) i$-139,731,344$-111,940,000
Levered Free Cash Flow (TTM) i$188.64M$-72,523,872
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: CureVac N.V. vs Maze Therapeutics Inc.

MetricCVAC (Jan 20, 2026)MAZE (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i6.96189.50
Forward P/E i-8.02-7.61
PEG Ratio i-0.35-5.25
Price to Sales (TTM) i14.83N/A
Price to Book (MRQ) i0.833.68
Market Capitalization
Market Capitalization i$1.05B$1.29B
Enterprise Value i$537.57M$998.67M
Enterprise Value Metrics
Enterprise to Revenue i6.53N/A
Enterprise to EBITDA i2.39-7.11
Risk & Other Metrics
Beta i1.84N/A
Book Value per Share (MRQ) i$5.63$7.20

Financial Statements Comparison: CureVac N.V. vs Maze Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCVAC (2024)MAZE (2025)
Revenue/Sales i621.09M0
Cost of Goods Sold i122.82MN/A
COGS % of Revenue i19.8%-
Gross Profit i498.27MN/A
Gross Margin i80.2%-
Research & Development i177.60M108.45M
Operating Income (EBIT) i206.20M-142.90M
Operating Margin i33.2%-
EBITDA i242.37M-140.50M
EBITDA Margin i39.0%-
Pre-Tax Income i221.52M-131.12M
Pre-Tax Income % of Revenue i35.7%-
Income Tax i33.30M0
Income Tax % of Revenue i5.4%-
Net Income (Profit) i188.22M-131.12M
Profit Margin i30.3%-

Balance Sheet & Liquidity Metrics

MetricCVAC (2024)MAZE (2025)
Cash & Equivalents i559.08M189.25M
Total Current Assets i610.91M349.72M
Total Current Assets % of Revenue i98.4%-
Total Current Liabilities i83.96M22.56M
Total Current Liabilities % of Revenue i13.5%-
Long-Term Debt i39.04M18.51M
Long-Term Debt % of Revenue i6.3%-
Total Shareholders Equity i808.43M354.97M
Retained Earnings i-1.63B-489.55M
Retained Earnings % of Revenue i-262.3%-
Property, Plant & Equipment i1.85M36.07M

Cash Flow Statement Comparison

MetricCVAC (2024)MAZE (2025)
Operating Cash Flow i42.53M-112.48M
Operating Cash Flow % of Revenue i6.8%-
Capital Expenditures i-16.61M-794,000
Free Cash Flow i96.80M-112.73M
FCF Margin i15.6%-
Debt Repayment i-5.93MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricCVACMAZE
Shares Short i547,3163.89M
Short Ratio i0.323.35
Short % of Float i0.49%9.32%
Shares Outstanding i225.17M49.34M
Float Shares i180.77M27.70M
% Held by Insiders i0.10%1.65%
% Held by Institutions i10.43%93.39%
% Held by Public i89.47%4.96%

Dividend Analysis & Yield Comparison: CureVac N.V. vs Maze Therapeutics Inc.

MetricCVACMAZE
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A